In the News

New study published in The Journal of Neuroscience highlights disease-modifying potential of Neurodon’s SERCA activators for Alzheimer’s disease

Neurodon CEO Dr. Russell Dahl to Present at the 20th FASEB Conference on Calcium and Cell Function

Accomplished Biotech Executive Frederick Beddingfield III, M.D., Ph.D. Joins Neurodon’s Board

Neurodon Joins the Longevity Biotechnology Association (LBA)

U.S. Senator Todd Young Visits Neurodon’s Facilities

Neurodon Awarded Nearly $3 Million from NIH to Advance its Drug for Alzheimer’s Disease

JDRF and Neurodon Partner to Advance Small Molecules Targeting a Key Pathway in Type 1 Diabetes Progression

Curative Potential for Diabetes, Alzheimer’s, and Parkinson’s

Neurodon Announces Initiation of IND-Enabling Studies for Diabetes

Neurodon Board Director Brunde Broady Releases New Book

Neurodon Announces Collaboration with Harvard Medical School

NIH grant to help advance Neurodon’s Alzheimer’s drug development

SERCA Activator may Improve Memory and Cognition for Alzheimer’s Patients

New Scientific Advisory Board Member

Neurodon Welcomes Brunde Broady to its Board of Directors

Neurodon Receives Funding from Elevate Ventures

Neurodon Awarded Phase I NIH STTR Grant

Neurodon Scientists Validated a New Way to Halt Brain Cell Loss